哌啶,4-亚丁基-1-(苯基甲基)- | 132439-21-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 哌啶,4-亚丁基-1-(苯基甲基)-
• 英文名称: N-benzyl-4-butylidenepiperidine
• 英文别名: 1-Benzyl-4-n-butylidenepiperidine；1-Benzyl-4-butylidenepiperidine
• CAS: 132439-21-5
• 化学式: C₁₆H₂₃N
• 分子量: 229.365
• InChiKey: FNDJPBCXMYYKSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  哌啶,4-亚丁基-1-(苯基甲基)- 在 palladium on activated charcoal 氢气 作用下， 以 溶剂黄146 为溶剂， 反应 12.0h， 以10.5 g的产率得到4-丁基哌啶
  参考文献：
  名称：

  （苯甲酰基苯基）哌啶：一类新的免疫调节剂。

  摘要：

  已经合成了一系列（苯甲酰基苯基）哌啶，并评估了其作为免疫调节剂的活性。这些化合物中的几种在基于对Con A，PHA和PWM的淋巴细胞促有丝分裂反应的基础上筛选中显示出良好的活性。苯甲酰基部分第4位的氯以及对哌啶核的氨基（或氨基甲酸酯衍生物）似乎对活性至关重要。所描绘的化合物可以被认为是新系列免疫调节剂的第一个实例。

  DOI：

  10.1021/jm00109a004
• 作为产物：
  描述：

  N-苄基哌啶酮 、 丁基三苯基溴化膦 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 10.0h， 生成 哌啶,4-亚丁基-1-(苯基甲基)-
  参考文献：
  名称：

  作为抗骨质疏松剂的（哌啶子基亚甲基）双（膦酸）衍生物的合成与评价。

  摘要：

  制备了一些（哌啶子基亚甲基）双（膦酸）衍生物，并评估了它们抑制甲状旁腺切除的大鼠的甲状旁腺激素诱导的血清钙升高的活性。几种（4-亚烷基-，4,4-二烷基-或4-烷基-4-卤代哌啶亚基）双（膦酸）衍生物表现出相当大的抑制活性。但是在哌啶环上具有芳族和极性取代基如叠氮基，羟基，氨基和酰胺基的化合物通常是无活性的。在这项研究中，两种4-亚烷基化合物（8a和8b）和4,4-环二烷基化合物（61）在静脉内或经口给药时均显示出强大的活性。

  DOI：

  10.1248/cpb.41.1971

文献信息

• Muscarinic agonists
  申请人：——

  公开号：US20020037886A1

  公开（公告）日：2002-03-28

  Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.

  提供了用于治疗疾病症状的化合物和方法，在这些疾病症状中，改变胆碱能，尤其是肌磷酸激酶m1、m4或m1和m4双重受体活性对疗效有益。在该方法中，向需要此类治疗的患者施用有效量的化合物。
• Compounds with activity on muscarinic receptors
  申请人：——

  公开号：US20030144285A1

  公开（公告）日：2003-07-31

  Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.

  本发明提供了化合物和方法，用于减轻或治疗通过改变毒蕈碱受体m1的活性具有益处的疾病或病症。在该方法中，向需要此类治疗的患者施用选择性毒蕈碱受体m1激动剂化合物的治疗有效量。
• COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS
  申请人：Brann Mark

  公开号：US20080108618A1

  公开（公告）日：2008-05-08

  Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.

  提供了化合物和方法，用于缓解或治疗改变毒蕈碱受体m1活性有益影响的疾病或状况。在该方法中，向需要此类治疗的患者施用选择性毒蕈碱受体m1激动剂化合物的治疗有效量。
• MUSCARINIC AGONISTS
  申请人：Andersson A. Carl-Magnus

  公开号：US20070155795A1

  公开（公告）日：2007-07-05

  Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.

  本发明提供了用于治疗疾病状态的化合物和方法，其中修改胆碱能，特别是肌动蛋白m1，m4或m1和m4的受体活性对疗效有益。在该方法中，向需要此类治疗的患者施用有效量的化合物。
• M2 Subtype preferring dibenzodiazepinone-type muscarinic receptor ligands: Effect of chemical homo-dimerization on orthosteric (and allosteric?) binding
  作者：Max Keller、Christian Tränkle、Xueke She、Andrea Pegoli、Günther Bernhardt、Armin Buschauer、Roger W. Read

  DOI：10.1016/j.bmc.2015.01.015

  日期：2015.7

  A series of new dibenzodiazepinone-type muscarinic receptor ligands, including two homo-dimeric compounds, was prepared. Sixteen representative compounds were characterized in equilibrium binding studies with [H-3]N-methylscopolamine ([H-3]NMS) at the muscarinic receptor subtype M-2, and seven selected compounds were additionally investigated at M-1, M-3, M-4 and M-5 with respect to receptor subtype selectivity. The side chain of the known M-2 preferring muscarinic receptor antagonist DIBA was widely varied with respect to chain length and type of the basic group (amine, imidazole, guanidine and piperazine). Most of the structural changes were well tolerated with respect to muscarinic receptor binding, determined by displacement of [H-3]NMS. Compounds investigated at all subtypes shared a similar selectivity profile, which can be summarized as M-2 > M-1 approximate to M-4 > M-3 approximate to M-5 (46, 50, 57, 62-64) and M-2 > M-1 approximate to M-4 > M-3 > M-5 (1, 58). The homo-dimeric dibenzodiazepinone derivatives UNSW-MK250 (63) and UNSW-MK262 (64) exhibited the highest M-2 receptor affinities (pIC(50) = 9.0 and 9.2, respectively). At the M-2 receptor a steep curve slope of -2 was found for the dimeric ligand 63, which cannot be described according to the law of mass action, suggesting a more complex mechanism of binding. In addition to equilibrium binding studies, for selected ligands, we determined pEC(50,diss), an estimate of affinity to the allosteric site of M-2 receptors occupied with [H-3]NMS. Compounds 58 and 62-64 were capable of retarding [H-3]NMS dissociation by a factor > 10 (E-max,E-diss >92%), with highest potency (pEC(50,diss) = 5.56) residing in the dimeric compound 64. As the monomeric counterpart of 64 was 100 times less potent (62: pEC(50),(diss) = 3.59), these data suggest that chemical dimerization of dibenzodiazepinone-type M receptor ligands can enhance allosteric binding. (C) 2015 Elsevier Ltd. All rights reserved.